Cytosorbents annual operating margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cytosorbents's operating margin was −39.79% for fiscal 2025.
View full Cytosorbents company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −39.79% | +6.43 pp |
| 2024 | 2024-12-31 | −46.22% | +56.56 pp |
| 2023 | 2023-12-31 | −102.78% | −11.91 pp |
| 2022 | 2022-12-31 | −90.87% | −38.18 pp |
| 2021 | 2021-12-31 | −52.69% | −27.40 pp |
| 2020 | 2020-12-31 | −25.29% | +50.76 pp |
| 2019 | 2019-12-31 | −76.05% | −6.80 pp |
| 2018 | 2018-12-31 | −69.25% | −4.29 pp |
| 2017 | 2017-12-31 | −64.96% | +75.08 pp |
| 2016 | 2016-12-31 | −140.04% | +54.12 pp |
| 2015 | 2015-12-31 | −194.17% | −26.98 pp |
| 2014 | 2014-12-31 | −167.19% | +27.36 pp |
| 2013 | 2013-12-31 | −194.55% | +65.39 pp |
| 2012 | 2012-12-31 | −259.94% | +12037.77 pp |
| 2011 | 2011-12-31 | −12,297.71% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −27.39% | +10.20 pp |
| Q1 2026 | 2026-03-31 | −34.34% | +10.21 pp |
| Q4 2025 | 2025-12-31 | −47.48% | −10.37 pp |
| Q3 2025 | 2025-09-30 | −30.17% | +25.90 pp |
| Q2 2025 | 2025-06-30 | −37.59% | +2.79 pp |
| Q1 2025 | 2025-03-31 | −44.55% | +7.25 pp |
| Q4 2024 | 2024-12-31 | −37.11% | +261.02 pp |
| Q3 2024 | 2024-09-30 | −56.08% | +27.34 pp |
| Q2 2024 | 2024-06-30 | −40.38% | +29.25 pp |
| Q1 2024 | 2024-03-31 | −51.80% | +31.72 pp |
| Q4 2023 | 2023-12-31 | −298.13% | −230.44 pp |
| Q3 2023 | 2023-09-30 | −83.42% | +27.75 pp |
| Q2 2023 | 2023-06-30 | −69.62% | +28.74 pp |
| Q1 2023 | 2023-03-31 | −83.51% | +6.13 pp |
| Q4 2022 | 2022-12-31 | −67.69% | +20.99 pp |
| Q3 2022 | 2022-09-30 | −111.17% | −55.78 pp |
| Q2 2022 | 2022-06-30 | −98.37% | −57.41 pp |
| Q1 2022 | 2022-03-31 | −89.64% | −62.73 pp |
| Q4 2021 | 2021-12-31 | −88.68% | −66.65 pp |
| Q3 2021 | 2021-09-30 | −55.39% | −36.81 pp |
| Q2 2021 | 2021-06-30 | −40.96% | −7.29 pp |
| Q1 2021 | 2021-03-31 | −26.91% | +1.56 pp |
| Q4 2020 | 2020-12-31 | −22.03% | +51.06 pp |
| Q3 2020 | 2020-09-30 | −18.58% | +73.75 pp |
| Q2 2020 | 2020-06-30 | −33.67% | +24.58 pp |
| Q1 2020 | 2020-03-31 | −28.47% | +54.07 pp |
| Q4 2019 | 2019-12-31 | −73.10% | +5.77 pp |
| Q3 2019 | 2019-09-30 | −92.33% | −45.13 pp |
| Q2 2019 | 2019-06-30 | −58.24% | +21.59 pp |
| Q1 2019 | 2019-03-31 | −82.54% | −12.59 pp |
| Q4 2018 | 2018-12-31 | −78.86% | −10.27 pp |
| Q3 2018 | 2018-09-30 | −47.20% | +15.12 pp |
| Q2 2018 | 2018-06-30 | −79.84% | −3.19 pp |
| Q1 2018 | 2018-03-31 | −69.95% | −19.93 pp |
| Q4 2017 | 2017-12-31 | −68.59% | +190.83 pp |
| Q3 2017 | 2017-09-30 | −62.32% | +26.59 pp |
| Q2 2017 | 2017-06-30 | −76.65% | +44.28 pp |
| Q1 2017 | 2017-03-31 | −50.02% | +65.44 pp |
| Q4 2016 | 2016-12-31 | −259.42% | −108.21 pp |
| Q3 2016 | 2016-09-30 | −88.91% | +71.13 pp |
| Q2 2016 | 2016-06-30 | −120.93% | +110.15 pp |
| Q1 2016 | 2016-03-31 | −115.46% | +197.52 pp |
| Q4 2015 | 2015-12-31 | −151.21% | +179.78 pp |
| Q3 2015 | 2015-09-30 | −160.04% | −32.40 pp |
| Q2 2015 | 2015-06-30 | −231.08% | −98.02 pp |
| Q1 2015 | 2015-03-31 | −312.99% | −204.32 pp |
| Q4 2014 | 2014-12-31 | −330.99% | −216.75 pp |
| Q3 2014 | 2014-09-30 | −127.63% | −27.73 pp |
| Q2 2014 | 2014-06-30 | −133.06% | +349.59 pp |
| Q1 2014 | 2014-03-31 | −108.66% | +274.35 pp |
| Q4 2013 | 2013-12-31 | −114.24% | +3.98 pp |
| Q3 2013 | 2013-09-30 | −99.90% | −0.59 pp |
| Q2 2013 | 2013-06-30 | −482.65% | +2572.56 pp |
| Q1 2013 | 2013-03-31 | −383.01% | +5934.55 pp |
| Q4 2012 | 2012-12-31 | −118.22% | — |
| Q3 2012 | 2012-09-30 | −99.31% | — |
| Q2 2012 | 2012-06-30 | −3,055.21% | — |
| Q1 2012 | 2012-03-31 | −6,317.56% | — |
Over the last five reported fiscal years, Cytosorbents's operating margin decreased from −25.29% to −39.79%, a change of −14.50 percentage points. The latest reported quarter, Q2 2026, shows −27.39%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cytosorbents filings at SEC.gov ↗